KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.87 $1.65 Friday, 26th Apr 2024 ADAP stock ended at $1.08. This is 1.42% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.83% from a day low at $1.03 to a day high of $1.09.
90 days $0.730 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Feb 19, 2021 $6.04 $6.31 $5.93 $6.29 881 179
Feb 18, 2021 $6.53 $6.54 $5.92 $5.98 1 938 150
Feb 17, 2021 $7.07 $7.09 $6.17 $6.62 1 644 514
Feb 16, 2021 $6.62 $7.17 $6.58 $6.77 1 959 877
Feb 12, 2021 $6.63 $6.75 $6.36 $6.52 852 123
Feb 11, 2021 $6.91 $7.26 $6.53 $6.63 1 281 791
Feb 10, 2021 $6.83 $6.97 $6.62 $6.77 782 602
Feb 09, 2021 $7.10 $7.34 $6.71 $6.75 1 457 160
Feb 08, 2021 $6.26 $7.28 $6.23 $6.83 2 114 283
Feb 05, 2021 $5.88 $6.26 $5.79 $6.21 960 630
Feb 04, 2021 $5.81 $6.02 $5.76 $5.84 625 502
Feb 03, 2021 $6.05 $6.14 $5.71 $5.77 909 185
Feb 02, 2021 $5.67 $6.04 $5.62 $6.03 1 033 820
Feb 01, 2021 $5.54 $5.64 $5.46 $5.61 547 943
Jan 29, 2021 $5.54 $5.74 $5.35 $5.46 709 040
Jan 28, 2021 $5.36 $5.64 $5.31 $5.48 1 007 276
Jan 27, 2021 $5.55 $5.60 $5.06 $5.29 1 796 548
Jan 26, 2021 $5.79 $5.95 $5.51 $5.59 784 142
Jan 25, 2021 $5.68 $5.96 $5.57 $5.75 811 177
Jan 22, 2021 $5.43 $5.72 $5.30 $5.60 576 655
Jan 21, 2021 $5.78 $5.83 $5.42 $5.42 869 035
Jan 20, 2021 $5.86 $6.06 $5.62 $5.79 806 940
Jan 19, 2021 $5.84 $5.96 $5.46 $5.94 1 093 076
Jan 15, 2021 $6.13 $6.20 $5.65 $5.72 1 593 042
Jan 14, 2021 $5.86 $6.38 $5.85 $6.10 1 466 220
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT